26 Feb 2021 - Anteris Technologies Limited (ASX:AVR) CEO & Managing Director Wayne Paterson talks about the benefits of the company's Anteris DurAVR aortic replacement valve to work better and for longer, company strategy and goals for 2021.
24 Feb 2021 - Shaw and Partners Chief Investment Officer Martin Crabb provides an update on the global economy, US stimulus packages, rising bond yields and their implications for investors.
22 Feb 2021 - Sequoia Financial Group Limited (ASX:SEQ) Managing Director Garry Crole talks about the company's strong 1H21 results on the back of increased trading activity, wealth management and continued growth in advisors.
18 Feb 2021 - QEM Limited (ASX:QEM) Managing Director, Gavin Loyden provides an update on the company's flagship Julia Creek vanadium and oil shale project in North Western Queensland, including work on the optimal processing route and the appointment of UK-based engineering consultancy GSA Environmental Limited (GSAe) to conduct vanadium extraction test work on Julia Creek shale.
10 Feb 2021 - Centuria Capital Group Limited (ASX:CNI) Joint CEO, John McBain talks 1H21 results & outlook, transactions and financial highlights.
05 Feb 2021 - Centuria Office REIT (ASX:COF) Fund Manager Grant Nichols discusses 1H21 highlights, the market conditions for leasing, and the outlook and trends for office markets.
03 February 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar talks about the company's collaboration agreement with the Walter Reed Army Institute of Research and UNSW into the study of a first-ever pharmaceutical treatment for traumatic brain injury, a top health priority for the military.
03 Feb 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook provides an update on the company's record December quarter results, progress with strategic partners and overseas expansion plans.
02 Feb 2021 - Centuria Industrial REIT (ASX:CIP) Fund Manager, Jesse Curtis talks 1H21 highlights, acquisitions, leasing activity and second half guidance.
29 Jan 2021 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its recent cap raising to support rapid USA commercialisation for Technegas following USFDA approval targeted in Q2 2021.
